Cardiac biomarkers are biologically measurable proteins found in blood that indicate damage or stress to the heart muscles. Common cardiac biomarkers include troponin, creatine kinase-MB (CK-MB), and myoglobin. These markers are routinely used in clinical settings to identify and evaluate cardiac conditions, such as myocardial infarction and congestive heart failure. Cardiac biomarker testing involves using blood tests to detect and measure biomarkers that help in diagnosis, prognosis, and guiding treatment of cardiac disease. Rapid point-of-care cardiac biomarker testing devices provide quick diagnosis and treatment without extensively delaying medical care.

The global Cardiac Biomarkers Market is estimated to be valued at Us$ 9836.55 Mn in 2024 and is expected to exhibit a CAGR Of 6.0% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The cardiac biomarkers market is expected to be flourished by the rising demand for point-of-care cardiac biomarker testing devices. Point-of-care devices help obtain biomarker results within 15-30 minutes, and enable quick clinical decision making and medical intervention. This is crucial in emergency care facilities and intensive care units for timely management of conditions like myocardial infarction. These portable devices are also increasingly adopted in pre-hospital settings by emergency medical responders and ambulance crews for rapid diagnosis during transport of suspected cardiac patients. Another major driver fueling the market growth is increasing prevalence of cardiovascular diseases worldwide owing to shifting lifestyles, growing geriatric population, and rising obesity and diabetes rates. According to World Health Organization estimates, cardiovascular diseases accounted for over 17 million deaths in 2015 and are projected to remain the leading cause of mortality globally by 2030.

Segment Analysis

The global cardiac biomarkers market is dominated by the diagnosis segment. This segment accounts for over 68% share of the global market as cardiac biomarkers find wide applications in diagnosing cardiovascular diseases. Within the diagnosis segment, myocardial injury sub-segment holds the largest share due to high incidence of myocardial infarction globally. The growing recommendations for cardiac troponin tests by clinical guidelines and regulatory bodies for diagnosis of myocardial infarction has further augmented the growth of this sub-segment.

PEST Analysis

Political: Governments across various countries are undertaking various initiatives to raise awareness about cardiovascular diseases and enhancing access to cardiovascular diagnostics and treatment. This is positively impacting the growth of the cardiac biomarkers market.

Economic: Rising healthcare spending coupled with growing per capita income is increasing the affordability of cardiovascular disease diagnosis and management, which is fuelling the cardiac biomarkers market growth.

Social: Growing geriatric population prone to cardiovascular diseases and changing lifestyle leading to increased risk of heart conditions are the major social factors driving the demand for cardiac biomarkers.

Technological: Advancements in assay technologies and development of high sensitivity troponin tests with improved accuracy are widening the applications of cardiac biomarkers. Introduction of automation in cardiac biomarker testing has further enhanced efficiency and lowered result turnaround time.

Key Takeaways

The Global Cardiac Biomarkers Market Demand is expected to witness high growth supported by rising geriatric population and growing burden of cardiovascular diseases worldwide.

Regionally, North America dominated the cardiac biomarkers market in historical years due to developed healthcare infrastructure and increasing adoption of advanced cardiac diagnostics. However, Asia Pacific is likely to demonstrate the fastest growth over the forecast period driven by growing healthcare expenditure, rising medical tourism, and increasing focus of market players in emerging countries.

Key players operating in the cardiac biomarkers market include Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMérieux SA. Abbott Laboratories leads the market with wide product portfolio in both laboratory-based as well as point-of-care cardiac biomarker testing systems. The other prominent players are focusing on developing high sensitivity troponin assays to expand their market share.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it